



Anti-Cancer Drug: Discovery, Development and Combination

Guest Editor:

Dr. Yasuyoshi Miyata

Department of Urology, Nagasaki
University Graduate School of
Biomedical Sciences, Nagasaki,
Japan

Deadline for manuscript
submissions:

closed (31 March 2020)

Message from the Guest Editor

Dear Colleagues,

Cancer is recognized as a multifactorial disease and its progression is regulated by extremely complex mechanisms. Furthermore, the contribution of such carcinogenic factors to malignant behavior is dependent on the type of cancer and the stage of the disease.

Armed with this knowledge, researchers have discovered many promising candidates for cancer therapy, and some are now being tested in clinical trials. Various new therapeutic targets, including chemical compounds and natural products, have been identified from basic and translational studies.

The aim of this Special Issue is to collect research papers, reviews, and communications focused on the discovery and development of anti-cancer drugs, as well as potential therapeutic targets, for various types of cancers. Moreover, clinical and translational studies on anti-cancer drugs used to improve the efficacy of conservative therapies, to decrease the number of residual cancer cells after operation, and to maintain the quality of life in patients with cancer, are invited.

Assoc. Prof. Yasuyoshi Miyata
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical
Biology and Phytochemistry,
University of Münster,
Corrensstrasse 48, D-48149
Münster, Germany

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Chemistry, Multidisciplinary*) / CiteScore - Q1 (*Chemistry (miscellaneous)*)

Contact Us

Molecules Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/molecules
molecules@mdpi.com
[X@Molecules_MDPI](https://twitter.com/Molecules_MDPI)